<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618314</url>
  </required_header>
  <id_info>
    <org_study_id>AT-03A-011</org_study_id>
    <nct_id>NCT05618314</nct_id>
  </id_info>
  <brief_title>Study of AT-527 in Subjects With Normal and Impaired Renal Function</brief_title>
  <official_title>A Phase 1, Open-Label, Parallel-Group, Single-Dose Adaptive Study to Evaluate the Safety and Pharmacokinetics of AT-527 in Adult Subjects With Normal and Impaired Renal Function Sub-Study: Effects of Probenecid on the Pharmacokinetics of AT-527 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atea Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atea Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of AT-527 in Subjects with Normal and Impaired Renal Function&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of AT-527 Maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of AT-527 Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of AT-527 AUC</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Volunteer</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Group A-Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose AT-527</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B-Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose AT-527</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C-Severe Renal Impairment (optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose AT-527</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D-End-Stage Renal Disease (optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of AT-527 pre- and post-dialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E-Matched Healthy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-527</intervention_name>
    <description>single dose AT-527</description>
    <arm_group_label>Group A-Mild Renal Impairment</arm_group_label>
    <arm_group_label>Group B-Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Group C-Severe Renal Impairment (optional)</arm_group_label>
    <other_name>Bemnifosbuvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-527</intervention_name>
    <description>Single dose of AT-527 pre- and post-dialysis</description>
    <arm_group_label>Group D-End-Stage Renal Disease (optional)</arm_group_label>
    <other_name>Bemnifosbuvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-527 and Probenecid</intervention_name>
    <description>Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19</description>
    <arm_group_label>Group E-Matched Healthy Subjects</arm_group_label>
    <other_name>Bemnifosbuvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must agree to use two methods of birth control from Screening through 90 days after&#xD;
             administration of the last dose of study drug&#xD;
&#xD;
          -  Females must have a negative pregnancy test at Screening and prior to dosing&#xD;
&#xD;
          -  BMI of 18.5 to 42.0 kg/m2&#xD;
&#xD;
          -  Willing to comply with the study requirements and to provide written informed consent&#xD;
&#xD;
        Subjects with Normal Renal Function (Group E):&#xD;
&#xD;
          -  Medically healthy, in the opinion of an Investigator&#xD;
&#xD;
          -  Normal renal function with eGFR ≥ 90 mL/min/1.73m2 at Screening&#xD;
&#xD;
        Renal Impaired Subjects (Groups A, B, and C):&#xD;
&#xD;
          -  Considered stable in the judgement of an Investigator&#xD;
&#xD;
          -  Presence of severe renal impairment (eGFR ≥ 15 and &lt; 30 mL/min/1.73m2), moderate renal&#xD;
             impairment (eGFR ≥ 30 and &lt; 60 mL/min/1.73m2) or mild renal impairment (eGFR ≥ 60 and&#xD;
             &lt; 90 mL/min/1.73m2) at Screening: renal impairment should have been stable for at&#xD;
             least 1 month prior to Screening.&#xD;
&#xD;
        Subjects with End-Stage Renal Disease -ESRD (Group D)&#xD;
&#xD;
          -  Considered clinically stable in the opinion of the Investigator&#xD;
&#xD;
          -  Presence of ESRD (eGFR &lt;15 mL/min/1.73m2 and being on intermittent hemodialysis) at&#xD;
             Screening and have been stable for at least 1 month prior to Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Infected with HIV or COVID-19&#xD;
&#xD;
          -  Abuse of alcohol or drugs&#xD;
&#xD;
          -  Use of other investigational drugs within 28 days of dosing&#xD;
&#xD;
          -  Other clinically significant medical conditions or laboratory abnormalities&#xD;
&#xD;
        Subjects with Normal Renal Function (Group E):&#xD;
&#xD;
        • Any clinically significant illness in the opinion of the investigator&#xD;
&#xD;
        Subjects with Impaired Renal Function (Group A, B, C and D):&#xD;
&#xD;
          -  History of renal transplant&#xD;
&#xD;
          -  Presence of poorly controlled Type 1 or Type 2 diabetes as defined by Hemoglobin A1c&#xD;
             (HbA1c) &gt; 10%&#xD;
&#xD;
          -  Subjects requiring treatment for renal impairment or other chronic disease must be on&#xD;
             a stable treatment plan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Atea Study Clinical Trials Administrator</last_name>
    <phone>8884811607</phone>
    <email>AteaClinicalTrials@ateapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Québec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atea Study Site</last_name>
      <phone>8884811607</phone>
      <email>ateaclinicaltrials@ateapharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 26, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Probenecid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

